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Abstract
Non-polymeric microspheres are stable-shaped particles constituted by crys-
talline organic compounds. This technology allows controlled release of parental 
products that has its prime value on estrogen therapy. The structure is a non-
polymeric crystalline microsphere that uses a low solubility fatty acid, cholesterol 
as a carrier. Cholesterol is a waxy lipid, a substance that is insoluble in water and 
has been recognized as safe as excipient by FDA for the manufacturing of drugs. 
Cholesterol is a lipid present in the cell membrane and subcellular organelles of 
tissues and serves as the building block for all steroid hormones including cortisol, 
aldosterone, estrogen, and testosterone; therefore, this fatty acid provides better 
biocompatibility than polymers. The use of cholesterol as a low solubility carrier 
was used to develop a first of its kind, parental HT product for the management of 
menopausal symptoms carrying estrogen microspheres in an aqueous suspension, 
which would allow an extended estrogen release maintaining plasmatic therapeutic 
concentrations. Estradiol doses would be up to 30 times lower than that provided 
by oral and transdermal routes fulfilling current recommendations regarding the 
use of a low dose and the nonoral route. Both intramuscular monthly administered 
formulations of E/P non-polymeric microspheres had favorable pharmacokinetic 
and safety profiles, suggesting this route as an interesting, novel, and suitable way 
of treating menopause-related symptoms.




In a classic study, the maximum concentration (Cmax) of estradiol at steady 
state was 161.54 and 98.82 pg/mL and reached at approximately 6 h after a single 
IM injection of 1.0 and 0.5 mg of estradiol, respectively. Estradiol concentrations 
decreased through day 4. At day 8, estradiol mean plasma concentration was 
between 20 and 30 pg/mL and remained stable through day 30. These concentra-
tions are equivalent to those found naturally occurring in early follicular phase 
of menstrual cycles (31 pg/mL median) in premenopausal women. The estradiol 
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elimination kinetics, based on EC MS, is biphasic, in which the elimination phase 
(a) presents a mean elimination half-life of 1.34–1.57 days and the second elimina-
tion phase (β) a mean elimination half-life of 12.22–16.78 days. Estradiol concen-
trations remained above 10 pg/mL during the 28 days of interval administration 
(Figure 1) [1].
The safety and effectiveness in menopausal symptoms treatment have been a 
primary goal in the last decades [2]. Microsphere technology uses of cholesterol as 
a carrier substance, and the IM administration allows for doses of estradiol up to 30 
times lower than those delivered by the leading oral and transdermal alternatives [3].
Due to this delivery system, which allows for an unmatched bioavailability of the 
active ingredients, non-polymeric microspheres provide comparable or improved 
efficacy outcomes than seen in the leading high dosage alternatives. At the same 
time, its low dose formulation results in a superior safety profile compared to other 
products [4].
Injectable slow release products allow for the formation of crystalline structures 
in the shape of microspheres, which use cholesterol as a carrier instead of the more 
commonly used polymers. Cholesterol NF, an inactive ingredient approved by 
the US Food and Drug Administration (FDA) for use in pharmaceutical special-
ties—including parenteral products, is generally considered safer than polymers. 
The highest proportion of cholesterol accepted within a parenteral pharmaceutical 
product is 5.2% (52 mg/mL); pharmaceutical alternatives that use this technology 
often contain 0.142% of cholesterol (1.42 mg/mL).
Today, HRT is coming under increasing public scrutiny as hormones in higher 
dosages are suspected of triggering certain forms of cancer, breast cancer; however, 
reduced dosages of estradiol are lowering these risks [5].
Millions of women entering menopause suffer from the well-known symptoms 
but are concerned that the benefits of currently available hormone replacement 
therapy (HRT) may not justify the suspected risks. Doctors have been looking for 
alternatives to HRT, such as phytopharmaceuticals, but have found them unsatisfac-
tory in relieving menopausal symptoms [5–8].
Figure 1. 
Estradiol serum profile. Monthly parenteral route of administration.
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A safe but effective alternative should be embraced not only by the medical com-
munity but also by the millions of women who suffer from menopausal symptoms 
[3, 9].
The hormonal transition process may last up to 10 years, with 3–4 years being 
average. Approximately, 50% of women who enter menopause suffer from meno-
pausal symptoms (hot flushes, excessive sweating, sleep disorders, weight increase, 
nausea, fatigue, irritability, depression). Because these symptoms can so often be 
debilitating, women are inclined to seek treatment [6].
Treatments can be grouped into three classes:
1. Hormonal treatments, most commonly available as a combination of an 
estrogen and a progesterone, or estradiol or other estrogens alone (for women 
who have had a hysterectomy).
2. Nonhormonal treatments:
a. medicines of natural origin, that is, herbal remedies such as Cimicifuga 
racemosa (leading product: Remifemin), Agnus castus; and soy and red 
clover isoflavones; and
b. antidepressants.
3. Traditional remedies: herbal teas, dietary measures, etc.
While the therapeutic efficacy of hormonal therapies has been proven, their use 
has declined due to perceived and real, safety concerns. It should be a convenient, 
effective, and low dose product that also addresses the safety concerns relevant to 
healthy women undergoing menopause [10].
2. Stable-shaped particles of crystalline organic compounds
This technology allows the controlled release of parenteral products and consists 
of the formation of crystalline arrangement in spherical particles, which use a low 
solubility excipient as a carrier instead of polymers. Cholesterol is a waxy type 
of lipid, a substance that is insoluble in water and has been recognized as safe as 
excipient by FDA for use in the manufacture of drugs and is also a lipid present in 
the cell membrane and subcellular organelles of tissues and serves as the building 
blocks for all steroid hormones, and the use of cholesterol gives better biocompat-
ibility than polymers.
The technology used for modification of the release of steroids has been applied 
in the development of products for the hormonal treatment of the climacteric 
symptoms (vasomotor symptoms such as night sweats, hot flushes, insomnia, 
memory loss/forgetfulness, mood swings), providing the clinician with an 
increased range of options in HRT.
2.1 About the technology
It is well known that many pharmaceutical actives are susceptible to crystal-
lize in different manners, depending on the conditions under which they are 
crystallized. The polymorphs or pseudopolymorphs are crystalline structures that 
resulting from crystallization of a substance. When the polymorphs are melted 
and cooled rapidly below their melting point, that is, melt-congealed, the atoms or 
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molecules forming most substances need some time to arrange themselves in the 
order most natural for the environment in which they are placed. Therefore, they 
remain in unstable amorphous or semiamorphous states or organize into metastable 
polymorphs.
Metastable polymorphs may be enantiotropic, and they can exist in more than one 
crystalline form. The molecular arrangement can diverge, such that one form is stable 
above the transition-point temperature and the other is stable below it. As a result, the 
crystal habit is dynamic and reversible depending on ambient conditions [11].
A natural process that suffers the metastable polymorphs is the “aging,” it is a 
natural crystallization process that occurs over time, transforming the metastable 
polymorphs into a more stable structure without human interference [12]. In the 
case of pharmaceutical manufacture, said process is usually costly, lengthy, unpre-
dictable, and dangerous. This is due to the interference of various factors [13].
It is important to consider the time at which the crystallization of metastable 
particles occurs due to which it can be deformed or destroyed in short time, for 
example, hours, impacting in the bioactivity and/or bioavailability of crystallized 
substances. We must be careful with the different dissolution rates of distinct poly-
morphs of a substance, which can produce loss of uniformity and stability between 
the batches of the same drug.
When a compound is administered, we often require suspension in an aqueous 
solution suitable for injection that should not overlook the stable crystallization [14].
When a compound is administered to a patient, said compound is subject to 
biological fluid that contains water, even before this compound is suspended in an 
aqueous medium.
In the case of pellets and implants, which are placed in the body at the time of 
surgical procedures, the previous also applies.
Thereof to achieve full crystallization of substance prior it is administered, it is 
necessary to assure the physical integrity of the shaped particles and uniformity in 
the release of the active principle.
With the purpose of improving the stability of therapeutic compounds, some 
researches have induced the crystallization of them, using a dispersion drying 
method with temperature being controlled (Matsuda et al. [15]).
Further solubility should consider the shape and size of the therapeutics par-
ticles, due to the dissolution of a solid that is also related to the surface erosion [16].
The preservation of the shape and particle size, independently of the form in 
which a compound is administered either as a solid or as a suspension, is an impor-
tant factor that assures the control and reproducibility of the bioavailability and 
biodynamics of the substance. Considering it, Kawashima et al. used two insoluble 
solvents for spherical crystallization of Tranilast and heat for the conversion of the 
resulting polymorphs of the process. Some experiments reported that the heat can 
accelerate the natural process of aging.
In some cases, the integrity or form of the substance could be seen compromised 
due to the heat requirements. Even though the reproducibility and stability is pos-
sible, the size control within the particles of the microspheres can be affected by the 
use of heat within the experiments.
The heat is also an important factor that can prevent reaching the desired stable 
polymorph of a specific substance, because in several cases, a hydrate is the most 
stable polymorphic form and the heat can dehydrate it. In the case of mixtures, the 
heating for stable crystallization is not recommended. Although the aging process is 
inferior to the heat method for obtaining stable polymorphs, it is also safer and has 
fewer limitations.
Among the studies carried out to induce crystallization of polymeric species that 
use solvent vapors, we highlight the putative crystallization, as well as the change 
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in the mechanical properties of polymeric compounds. To transform a polymer 
matrix, Pr4VOPc dye (vanadyl phthalocyanine having four propyl substituents), 
from glassy phase I to crystallized phase II, and organic solvent vapors [17] also 
have been used.
Tang et al. used organic solvent vapors.
2.2 Characteristics of the technology
The crystalline organic compounds might be formed by homogeneous particles 
of a single organic compound, or well, they might be formed by mixtures of two 
or more organic compounds. In aqueous suspension, it is normal that during pro-
longed storage, the stable particles preserve a constant shape and size. Its features 
are particularly essential and advantageous in pharmaceutical formulations, due 
to which stable particles can be fabricated to a uniform size and shape, retaining 
said characteristics despite of the long-term storage.
The process involves exposure to an atmosphere saturated with solvent vapors, 
the shaped particles above mentioned, so that one or more organic compounds are 
in a crystalline, amorphous, or metastable form. Of the liquids used as solvents, at 
least one or more organic compounds must be soluble.
Among benefits offered by process, it is found that it may be applied to hydrates, 
which are the most stable polymorphs. Its stability allows the integration of water 
molecules to crystalline web during formation, since said polymorphs will not drive 
off water molecules. Due to its susceptibility to high temperatures, the process is 
also applicable to thermolabile substances. With the exception of the compositions 
of mixtures-eutectic, a great variety of mixtures involved in the formation of stable 
structures could not be achieved by means of a process involving heat.
This leads to the utilization of a method that involves crystallization or recrystal-
lizing of an amorphous or metastable crystalline organic compound or mixture. The 
method consists of the following steps:
1. exposing said compound or mixture to an atmosphere saturated with the 
vapors of one or more liquids, at least one of which must be a solvent for said 
compound or mixture, for a time sufficient for transforming the metastable 
compound or mixture to a stable, crystallized compound, or mixture; and
2. recovering the stable, crystallized compound or mixture for storage or use.
To carry out the process, any container can be used where they can manipulate 
the different variables, such as volume, pressure, temperature, and atmospheric 
content. The desired solvent vapors can be contained in a chamber with atmosphere 
saturated. Once the vapors fill the chamber without causing condensation on the 
surfaces of the chamber or the particles, the saturation point is reached.
The particles formed preferably acquire shapes of microsphere, pellet, or 
implant. Although it can be affected by melt-congealing, these are the preferred 
shaped particles that have uniform and reproducible surface area. The particles 
formed are usually configured to obtain a uniform particle size or range of sizes. 
Any process is susceptible to be used as long as it achieves a metastable crystalline 
conglomeration. The said methods should consider the crystallization of a mixture, 
and the mixture may be eutectic or noneutectic.
To be exposed to solvent vapors, the particles should be placed in the chamber 
or some other suitable container; however, said particles should not be immersed or 
in contact with any other liquid solvents. Once in the chamber, the particles are in a 
stationary or mobile state.
Estrogen
6
Depending on the consistency with the established principles, the optimal time 
necessary to carry out the crystallization will vary, that is, the physicochemical 
characteristics of the substances, such as size of the particle, the chemical makeup 
of the particle, the form of the solid state of the particle (i.e., amorphous, metasta-
ble crystalline), the type and concentration of solvent used, and the temperature of 
the treatment. These physicochemical properties will determine if the crystalliza-
tion process requires seconds or even hours (normally 1–40 h are required, prefer-
ably, 1–36 h). A 24-h exposure time seems to be effective. The time ranges do not 
seem to be modified by the previous partial crystallization of the particles. Other 
important characteristics that also impact on the optimization of the exposure time 
of the substance and therefore on the crystallization of it are the solvent system 
used by the organic compound(s) to be crystallized.
As mentioned above, one of the main advantages of the process is that it can be 
applied to thermolabile substances, which are susceptible to high temperatures, 
which exactly what is sought is to avoid them. Thus, particular compound is what 
will define the applicable temperature range used in the process. To obtain vapor-
ization of the solvent, it is sufficient that the temperature of the vapor in atmo-
sphere is below the melting point of the particles.
The process requires the use of any agent classified as a solvent for the organic 
compound of interest. Therefore, the latter will determine the selection of the 
solvent. Among the conventional liquid solvents used in the laboratory are the 
following examples: water, alkanes, alkenes, alcohols, ketones, aldehydes, ethers, 
esters, various acids including mineral acids, carboxylic acids and the like, bases, 
and mixtures thereof. Methanol, ethanol, propanol, acetone, acetic acid, hydro-
chloric acid, tetrahydrofuran, ether and mixed ethers, pentane, hexane, heptane, 
octane, toluene, xylene, and benzene are some specific exemplary solvents. Water is 
an especially useful component of a solvent/liquid mixture, particularly where the 
most stable polymorph of a substance is a hydrate. Generally, solvents suitable for 
conventional liquid recrystallization of the compound of interest are suitable as a 
solvent in the present method.
The compound(s) of the stable particles include any organic compound capable 
of existing as a crystalline solid at standard temperature and pressure. The stable 
crystalline solid is formed by particles that are comprised by one or more organic 
compound(s). The said stable crystalline solid is a lattice of discrete organic mol-
ecules, i.e., nonpolymeric.
In the process, those organic compounds having some pharmacological or 
therapeutic activity are preferred. Even more preferred are the pharmacological 
compounds susceptible to the formation of polymorphs. These include particles 
comprised of a steroid or sterol, either, estrogen, androgen and progestogen, such 
as, 17P-estradiol, testosterone, progesterone, cholesterol, or mixtures thereof. Some 
nonsteroidal components that can be included in said mixtures are oxatomide/cho-
lesterol, nifedipine/cholesterol, and astemizole/cholesterol.
The particles can be stored in liquid suspensions such as aqueous media, or 
administered directly to the patient. Due to stabilization of particles of amor-
phous or metastable crystalline organic compounds, the particles can be stored 
in liquid suspension, such as aqueous medium, or administered directly to a 
patient.
2.2.1 Stable-shaped particles of one or more allotropic molecular organic compounds
Allotropic organic compounds can assume two or more distinct physical forms 
(e.g., different crystalline forms or an amorphous versus a crystalline form). The 
polymorphs or polymorphic species are allotropic species.
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It is important to consider the pharmaceutically acceptable excipients, stabi-
lizers, and buffers, which conform shaped particles and contribute to the stable 
storage of them.
Among the advantages of stable-shaped particles is the combination of physico-
chemical properties. First, the particles are configured into desired shapes by means 
that might not result in the most stable crystalline form of the constituent organic 
compound. In the solid state crystallization process, the organic compound will 
assume the most stable crystalline structure, facilitating the retention of the size 
and shape of the original particle.
A configured particle that comprises of one or more molecular organic com-
pounds, each one which has a uniform crystalline character and possessed of a high 
degree of storage stability, is the resultant product.
There are several characteristics that lead to the particular predictability and 
consistent bioavailability and associated biodynamics, such as, the combination of 
the uniformity of size and shape of the particle and the uniformity and stability of 
the crystalline structure of the constituent organic compound.
The particle size and the shape of microspheres are prefabricated to desired 
conditions. Thus, the particles are subject to a solid-state crystallization process 
that stabilizes the compounds of the particles without loses the size and shape with 
which they were manufactured.
The resulting particles have greater uniformity of size and shape, more uniform 
and predictable dissolution profiles, and greater storage stability in various forms, 
e.g., in liquid suspension such as aqueous media or other storage liquid, as lyophi-
lized solid, or alone as a powder or dry solid. By storage stability, it is meant that 
the particles have improved shelflife without the loss of their desired uniformity 
in size and shape, per se. That is, if the desired particle shape is a microsphere, 
the particles will retain a spherical shape of constant size over periods exceeding 
several years.
Here, storage stability refers to retention of the original size and shape of the 
particle, as well as the pharmacological activity of the active agent over a period of 
at least one .
The technology also involves a method of crystallizing shaped particles of a 
metastable compound or mixture of compounds without dissolution of the particle 
and loss of the desired shape.
The crystallization process is affected by exposing said particles to a controlled 
atmosphere saturated with the vapors of a solvent or solvents. The atmosphere is 
optionally modified in other respects, for example, pressure, temperature, inert 
gases, etc. Preferably, the controlled atmosphere is saturated with a solvent vapor 
but not so much as to effect condensation of said solvent.
More particularly, the method affects crystallization of an amorphous or meta-
stable organic compound in a shaped particle without alteration of the dimensions 
(e.g., size and shape) of said particle which comprises of: (i) exposing said shaped 
particle to an atmosphere saturated with the vapor of a liquid, said liquid being a 
solvent for said organic compound and (ii) recovering said shaped particle wherein 
the said organic compound is of a uniform crystalline structure.
Alternatively stated, the method involves effecting a solid-state crystallization 
of a molecular organic compound in a particle of definite size and shape compris-
ing of: (i) exposing said particle to an atmosphere saturated with a solvent for 
said organic compound; and (ii) recovering said particle, wherein said organic 
compound in said recovered particle is of a uniform crystalline structure and said 
recovered particle has retained said size and shape. Retaining the size and shape of 
the particle is meant to include minor variations in the dimensions of the particle, 
for example, no more than about 15%, preferably, no more than about 10%.
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This technology provides a means for fabricating particles of desired dimension 
without regard to the resulting allotropic form of the organic compound. After 
the particle is fabricated into the desired shape and size, the solid state crystalliza-
tion can be affected to crystallize the organic compound into a storage-stable solid 
state of uniform crystal structure. Moreover, the solid state crystallization can be 
affected on particles composed of more than one allotropic organic compound.
Preferably, the shaped particle is a microsphere, and, as a result of the present 
process, the organic compound(s) of the microsphere are ordered into a single, 
homogeneous crystalline form without any deterioration in the size or shape of the 
microsphere.
The term “crystallization” refers to a process by which the most stable poly-
morph of a particular substance is achieved. Recrystallization refers to a process 
similar to crystallization except that the organic compound of the particle, rather 
than being amorphous, was initially only partially crystalline, with a mixed crystal-
line habit, or crystalline, but of a less stable form. Unless indicated otherwise, the 
term crystallization includes recrystallization.
The term “solid state crystallization” refers to a crystallization process that is 
affected without macroscopic dissolution of the compound being crystallized. As 
used herein, solid state crystallization includes a crystallization process wherein 
an organic compound within a shaped particle is crystallized or recrystallized by 
exposure to a solvent vapor without loss or alteration of the shape or size of the 
particle. It will be appreciated by those skilled in the art that while subtle intermo-
lecular changes will be affected by such crystallization (e.g., creation or rearrange-
ment of crystal lattice structure), the microscopic and/or macroscopic dimensions 
of the particle will not be appreciably altered. The term “saturated” when used in 
reference to the atmosphere wherein the crystallization is conducted means that 
the atmosphere within the chamber or enclosure used to hold the solvent vapors 
contains the maximum quantity of said solvent in the vapor phase without affect-
ing visible condensation on surfaces within the chamber. Condensation does not 
include microscopic condensation on the surface of the particles that does not affect 
their shape.
The term “solvent” refers to a liquid at standard temperature and pressure, and 
one capable of solubilizing an appreciable amount of a specified solid solute. The 
solid solute will be a particular organic compound. Solids vary from 0 to 100% in 
their degree of solubility [18].
A liquid will be a considered a solvent with respect to a particular solid solute 
provided the solute is at least 10% soluble in said liquid.
The term “particle” refers to a discrete collection of a plurality of molecules of 
one or more organic compounds. As used herein, a particle may be an ordered col-
lection (e.g., crystalline) or disordered collection (e.g., amorphous) of molecules, 
or any combination thereof. The term embraces, among other things, microscopic 
as well as macroscopic particles such as powders, microspheres, pellets, implants, 
and the like.
Preferably, particles are made of microspheres. The preferred microspheres 
range in size from 1 micron to 1 mm, more preferably 1 to 500 microns, and most 
preferably in the range of 1–100 microns, particularly for human use. When the 
particles are in pellet form, such particles are normally but not necessarily cylindri-
cal with lengths of 1000–5000 microns and diameter of 500–1000 microns. These 
particles can have important applications for veterinary use and are not injected but 
deposited under the skin.
The size and shape of the particle will depend on the intended application and 
the constituent organic compound(s). For example, microsphere size is chosen for 
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practical reasons, that is, a size appropriate for administration using a hypodermic 
needle or for assuring a desired rate of dissolution.
The term “molecular organic compound” refers to an organic compound 
existing as stable discrete molecules (i.e., nonpolymeric) and when combined with 
a plurality of identical molecules, it is capable of assuming one or more ordered 
crystalline structures. Thus, a molecular organic compound is meant to distinguish 
from a polymeric species.
The term “metastable” means a pseudoequilibrium state of a solid substance 
where the content of free energy is higher than that contained in the equilibrium 
state. A “stable” substance or particle has a crystalline structure whose shape 
remains unchanged in a standard ambient environment, e.g., in air having vary-
ing levels of moisture, for an extended period. However, it should be understood 
that “stable” does not indicate infinite stability but means sufficiently stable such 
that the particles remain sufficiently stable for the preservation of their crystalline 
characteristics during storage and up to their application and use and additionally, 
after they have been administered to a subject, up to their total dissolution.
The technology also encompasses stable microspheres achieved using the pres-
ent method. Such microspheres preferably contain a compound having pharmaceu-
tical applications. The microspheres and pellets are useful in human, as well as in 
animal, therapeutic regimens.
For instance, there is currently a need for compositions that accomplish the sus-
tained release of steroid growth promoters in food animals to promote the growth 
of such animals. The amount of growth hormone administered to an animal would 
depend on the particular animal species, hormone, length of treatment, age of 
animal, and amount of growth promotion desired. The particles can be particularly 
configured for optimal delivery by injection by varying the particle size.
As discussed above, the microspheres are stable in aqueous fluids and are thus 
amenable to parenteral injection. Some examples of modes of administration are 
(IV), intraarterial (IA), intramuscular (IM), intradermal, subcutaneous, intraar-
ticular, cerebrospinal, epidural, intraperitoneal, etc. In addition, the compounds 
can be administered via an oral route, either as an aqueous suspension or a lyophi-
lized product. Other routes of administration are also acceptable, including topical 
application, into the eye, or via inhalation in the form of droplets or mist.
The dosage may take the form of a microsphere powder in vials/ampoules, 
ready to be prepared as suspensions, or take the form of ready-prepared suspen-
sions, packaged into injectable ampoules or directly into syringes, ready to be 
administered in human or veterinary medicine. The suspension medium may be 
water, a saline solution, an oil, containing buffers, surfactants, preservatives, com-
monly used by pharmacotechnicians for preparing injectable substances, or any 
other substance or combination, which does not threaten the physical and chemi-
cal integrity of the substances in suspension and which is suitable for the organism 
which will receive it. If it is desired to avoid a sudden initial increase in the level 
of active ingredient in the internal medium of the receiving organism, it will be 
preferable in the case of ready-for-use suspensions to use liquid vectors in which 
said active ingredients are practically insoluble. In the case of active substances, 
partially soluble in the lukewarm liquid vector but insoluble at cold temperature, 
it is preferable, from the pharmacological point of view, to avoid the formation 
of precipitates (called “caking effect”) by preparing formulations in the form of 
separate microsphere powder and liquid vector, which will be mixed only at the 
time of injection.
For most applications in human medicine (duration of action of the active 
ingredient between a circadian cycle and a menstrual cycle), it is preferable to use 
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microspheres whose diameter is between 5 and 100 microns, depending on the 
combinations of active substances/carrier substances.
A separation of microspheres according to their diameter may be performed 
during the manufacturing process using known processes: for example, by cyclonic 
separators, by sieving using air suction or by sieving in aqueous medium. In prac-
tice, it is sufficient if more than 70% of the microspheres have diameters between 
70 and 130% of a specified diameter. If necessary, the ideal dissolution curve, 
determined by the proposed application, may be approached by mixing batches 
with suitable different diameters. Moreover, particles that do not comply with the 
specifications may be recycled.
The mechanism by which substances in a solid state crystallize in the pres-
ence of vapors containing at least one solvent has not yet been established. 
The crystallization process may well conform, as regards the effect of the 
solvents, to the traditional principles that apply in saturated solutions and in 
molecular mobility.
It is possible that some molecular rotational or transference movement occurs, 
which seems to depend on the particular type of solvent used and to the tempera-
ture of vaporization [19].
.It is clear, however, that the temperatures at which the crystallization is 
obtained are well below vitreous transition temperatures and are in fact only in 
accordance with that required for the solvents’ vapor pressure. Without wishing 
to be bound by any theory, we contemplate that the vapor molecules of the solvent 
or five solvents might form microcondensations and minute accumulations of 
solvent on the surface of the particles to be crystallized, thus bringing sufficient 
energy for the surface molecules of the solid particles to form organized struc-
tures (e.g., crystalline domains). By the same token, if present in the vapor, water 
molecules become available for the formation of hydrates, when required for stable 
polymorphs.
Once the organizational and/or water-absorbing process starts at the surface, 
it is possible that the crystallization process gradually spreads into the interior of 
the particle without the need for contact with or dissolution within the solvent. 
If this is correct, there are two facts, which seem to indicate that these microcon-
densations or molecular agglomerations, are extremely minute. Firstly, if enough 
solvent condensation occurred on the surface of the particle, the solvent would at 
least partially dissolve it and modify its shape. To avoid any partial dissolution, the 
amounts deposited by the vapor must be extremely minute.
Secondly, during exposure to solvent vapors, the particles, because of their small 
size and large quantity, inevitably come in contact with one another. If there is any 
surface dissolution of the particles, as would occur if the substantial quantities of 
amounts of deposited vapor were not very minute, the particles would tend to stick 
to each other and form lumps or agglomerates. Under the conditions described 
herein, this does not occur.
3. Examples
3.1 Example 1: microspheres of 17-beta-estradiol
The spherical 17-beta-estradiol is prepared by spraying at 210°C and solidified at 
−50°C (spray/congealing method). In this stage, the ME are formed by amorphous 
solids (Figure 1), which when put in contact with water at 40°C, are deformed by 
the growth of crystals on their surface. In order to obtain the microspheres with 
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the thermodynamically more stable crystalline form, a hemihydrate, the spheres 
are stored in an atmosphere saturated with vapors of a mixture of ethanol: water 
(50:50), for 4 h at a temperature of 20 and 25°C. Finally, the microspheres are stored 
at 40°C to remove the solvent (Figure 2). At the end of the process, the spheres are 
stable, since no change in their morphology is observed after being stored in water 
at 40°C for more than 9 months.
3.2 Example 2: testosterone microspheres
Two polymorphs and two testosterone hydrates are published in the literature, 
hydrates being thermodynamically more stable. The preparation of the testosterone 
microspheres has the same preparation steps that were used for the estradiol micro-
spheres. The stabilization or crystallization was made by storing the microspheres 
in a saturated atmosphere of vapors of a solution of acetone: water (80:20). The 
physical stability was evaluated by microscopic observation of storage microspheres 
in water at 40°C; the freshly prepared testosterone microspheres (uncrystallized) 
were unstable, while the crystallized microspheres were stable for more than 
40 days.
3.3 Example 3: progesterone microspheres
The unstable or metastable spherical solids of progesterone are obtained 
with the same method (spray/congealing) described in the previous examples. 
Progesterone has two polymorphic forms, form I have a melting temperature of 
131°C and form II with a melting temperature of 123°C, of which form I has a 
thermodynamically most stable structure.
To obtain the microspheres in the most stable crystalline form, they were stored 
in an atmosphere saturated with vapors of an ethanol solution: water (50:50) at 
room temperature for 4 h. The crystallization kinetics of the microspheres was 
studied by thermal analysis (DSC), where it was observed that polymorph II is the 
crystalline form that is first formed and later transformed into polymorph I, by the 
vapors of the solvent mixture.
In the crystallized microspheres, no change in their surface was observed after 
6 months of storage in water at 40°C.
Figure 2. 
Estradiol microsphere: estradiol/cholesterol 1:1.
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3.4 Example 4: astemizole microspheres
In the same way that the microspheres formed by spheroidal molecules (spray/con-
gealing) are obtained, the microspheres of astemizole are prepared, crystallized with 
vapors of ethyl acetate or acetone. Its physical stability was confirmed after observing 
under the microscope spheres stored in water at 40°C for more than 2 months.
3.5 Example 5: astemizole pellets
Pellets obtained in a conventional manner were stabilized with the follow-
ing crystallization method. When the microspheres were placed in a recipient of 
approximately 7 L and exposed for 24 h at 20–25°C to the vapors of 2 mL of ethanol 
kept in a porous cellulose material, the initially amorphous microspheres crystal-
lized completely in the presence of the vapors.
The microspheres were later dried at 60°C in a vacuum for 24 h, and the residual 
ethanol present in the microspheres was less than 0.01%.
3.6 Example 6: cholesterol microspheres
Cholesterol microspheres were prepared by the spray/congealing method, 
through microscopic observations of microspheres stored in water, it was concluded 
that the spheres obtained are formed by amorphous solids.
The crystallization of the spheres is possible by storage in atmospheres of acetic 
acid at 30°C for 8 h.
3.6.1 Crystallization of substance mixture
The obtaining of spherical particles from mixtures of materials is particularly 
interesting in the pharmaceutical industry since the end products can have differ-
ent kinetic (dissolution rates), and chemical (stability) properties to the materials 
separately. The possibility of stabilizing spheres of material mixtures with this tech-
nology greatly increases its application in health areas. To prepare stable spheres 
formed by mixing of substances, it is important that the materials are thermally 
stable and chemically compatible.
3.7 Example 7: microspheres of 17-beta-estradiol: cholesterol (40:60)
The microspheres of the mixture were obtained by the spray/congealing 
method. The stabilization by the crystallization method with solvent atmospheres 
was possible with the use of 96% by weight ethanol at a temperature of 30°C for 
24 h. To remove the solvent, the microspheres were stored in an oven at 60°C. To 
study the physical stability, the microspheres are stored in water at 40°C and 
observed under a microscope, after 82 days, the crystallized microspheres retain 
their spherical shape while those that were not crystallized are deformed by crystals 
on the surface.
3.7.1 Stability in vivo
In the case of slow release injected or implanted medicinal drugs, the physi-
cal integrity of the particles after their administration to the patient is essential 
to assure the desired rates of delivery and the reproducibility of effect. Thus, the 
stability in vivo of the microspheres described in the previous example was checked 
in New Zealand male rabbits.
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Microscopy photographs was taken 1, 4, 7 and 14, 10 days after intramuscular 
injection showed that the microspheres remain whole, until they have finally 
dissolved. For comparison, microspheres that had not been crystallized were also 
injected. Their microscopy photographs showed that these microspheres changed 
into nonspherical shapes.
3.8 Example 8: microspheres of a mixture of 10% 17-beta-estradiol and 
90% cholesterol
As for the previous example, the microspheres of this mixture were obtained by 
melting together the components, sprayed into droplets and congealed into micro-
spheres. Initially, they showed a high amorphous content.
When the microspheres were placed in a recipient of approximately 7.0 L and 
exposed for 24 h at 0°C, to the vapors of 8 mL of ethanol kept in a porous cellulose 
material, the initially amorphous microspheres crystallized completely in the pres-
ence of the vapors.
The microspheres were later dried at 60°C in a vacuum for 24 h and the residual 
ethanol present in the microspheres was less than 0.01%.
To evaluate stability of the crystallized microspheres, they were placed in aque-
ous solution at 40°C and observed by optical microscopy after 141 days.
3.9 Example 9: microspheres of a mixture of 95.2% progesterone and 
4.8% 17-beta-estradiol
As for the previous examples, the microspheres of this mixture were obtained 
by melting together the components, sprayed into droplets, and congealed into 
microspheres. Initially, they showed a high amorphous content.
When the microspheres were placed in a recipient of approximately 7 L and 
exposed for 24 h at 20–25°C to the vapors of 2 mL of ethanol kept in a porous cel-
lulose material, the initially amorphous microspheres crystallized completely in the 
presence of the vapors.
The microspheres were later dried at 60°C in a vacuum for 24 h, and the residual 
ethanol present in the microspheres was less than 0.01%.
3.10 Example 10: microspheres of a mixture of 60% progesterone and 
40% cholesterol
As for the previous examples, the microspheres of this mixture were obtained by 
melting together the components, sprayed into droplets and congealed into micro-
spheres. They initially showed a high amorphous content.
When the microspheres were placed in a recipient of approximately 7 L and 
exposed for 24 h at 30°C to the vapors of 2 mL of ethanol kept in a porous cellulose 
material, the initially amorphous microspheres crystallized completely in the pres-
ence of the vapors.
The microspheres were later dried at 60°C in a vacuum for 24 h and the residual 
ethanol present in the microspheres was less than 0.01%.
4. Conclusion
This technology is widely applicable in forming stable, crystallized particles, 
microspheres, and pellets of a variety of organic compounds and mixtures that 
Estrogen
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maintain their shape in aqueous solution. Hence, the present method should find 
significant utility in the manufacture of pharmaceuticals and pharmaceutical 
compositions, particularly where treatment calls for administration of the pharma-
ceutical in a slow release formulation. This can be translated into low doses, more 
secure treatment alternatives, with less frequent side effects, and as an alternative 
route of administration.
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